Colistin versus polymyxin B for the treatment of patients with multidrug-resistant Gram-negative infections: a systematic review and meta-analysis

International Journal of Antimicrobial Agents

Volumn 49, Issue 2, 2017, Pages 233-238

  Vardakas, Konstantinos Z ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gram negative bacteria; MDR; Predictor; Renal failure; XDR

Indexed keywords

COLISTIN; CREATININE; POLYMYXIN B; ANTIINFECTIVE AGENT;

ABDOMINAL INFECTION; AGE; ARTICLE; BACTEREMIA; BODY WEIGHT; COMPARATIVE EFFECTIVENESS; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; GRAM NEGATIVE INFECTION; HOSPITAL ADMISSION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY INJURY; META ANALYSIS; MORTALITY; MULTIDRUG RESISTANT GRAM NEGATIVE INFECTION; NEPHROTOXICITY; PREDICTOR VARIABLE; RISK; SYSTEMATIC REVIEW; TREATMENT DURATION; ACUTE KIDNEY INJURY; COMPARATIVE STUDY; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MULTIDRUG RESISTANCE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ANTI-BACTERIAL AGENTS; COLISTIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXIN B; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84995790818     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2016.07.023     Document Type: Article

References (30)

1. [1] Falagas, M.E., Kasiakou, S.K., Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005), 1333–1341.
2. [2] Ni, W., Cai, X., Wei, C., Di, X., Cui, J., Wang, R., et al. Efficacy of polymyxins in the treatment of carbapenem-resistant Enterobacteriaceae infections: a systematic review and meta-analysis. Braz J Infect Dis 19 (2015), 170–180.
3. [3] Falagas, M.E., Rafailidis, P.I., Ioannidou, E., Alexiou, V.G., Matthaiou, D.K., Karageorgopoulos, D.E., et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents 35 (2010), 194–199.
4. [4] Nation, R.L., Li, J., Cars, O., Couet, W., Dudley, M.N., Kaye, K.S., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15 (2015), 225–234.
5. [5] Gales, A.C., Jones, R.N., Sader, H.S., Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006–09). J Antimicrob Chemother 66 (2011), 2070–2074.
6. [6] Sader, H.S., Rhomberg, P.R., Farrell, D.J., Jones, R.N., Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide. Diagn Microbiol Infect Dis 83 (2015), 379–381.
7. [7] Pedersen, M.F., Pedersen, J.F., Adsen, P.O., A clinical and experimental comparative study of sodium colistimethate and polymyxin B sulfate. Invest Urol 9 (1971), 234–237.
8. [8] Kassamali, Z., Danziger, L., To B or not to B, that is the question: is it time to replace colistin with polymyxin B?. Pharmacotherapy 35 (2015), 17–21.
9. [9] Phe, K., Lee, Y., McDaneld, P.M., Prasad, N., Yin, T., Figueroa, D.A., et al. In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy. Antimicrob Agents Chemother 58 (2014), 2740–2746.
10. [10] Rigatto, M.H., Oliveira, M.S., Perdigao-Neto, L.V., Levin, A.S., Carrilho, C.M., Tanita, M.T., et al. Multicenter prospective cohort study of renal failure in patients treated with colistin versus polymyxin B. Antimicrob Agents Chemother 60 (2016), 2443–2449.
11. [11] Bellomo, R., Ronco, C., Kellum, J.A., Mehta, R.L., Palevsky, P., Acute renal failure—definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004), R204–12.
12. [12] Effect estimates and generic inverse variance meta-analysis. In: Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration http://handbook.cochrane.org/, 2011 accessed 20.09.16.
13. [13] Rottier, W.C., Ammerlaan, H.S., Bonten, M.J., Effects of confounders and intermediates on the association of bacteraemia caused by extended-spectrum β-lactamase-producing Enterobacteriaceae and patient outcome: a meta-analysis. J Antimicrob Chemother 67 (2012), 1311–1320.
14. [14] Oliveira, M.S., Prado, G.V., Costa, S.F., Grinbaum, R.S., Levin, A.S., Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity. Diagn Microbiol Infect Dis 65 (2009), 431–434.
15. [15] Akajagbor, D.S., Wilson, S.L., Shere-Wolfe, K.D., Dakum, P., Charurat, M.E., Gilliam, B.L., Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Clin Infect Dis 57 (2013), 1300–1303.
16. [16] Tuon, F.F., Rigatto, M.H., Lopes, C.K., Kamei, L.K., Rocha, J.L., Zavascki, A.P., Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium. Int J Antimicrob Agents 43 (2014), 349–352.
17. [17] Bianco, T.M., Dwyer, P.N., Bertino, J.S. Jr, Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients. Antimicrob Agents Chemother 33 (1989), 1890–1895.
18. [18] Levy, E.M., Viscoli, C.M., Horwitz, R.I., The effect of acute renal failure on mortality. A cohort analysis. JAMA 275 (1996), 1489–1494.
19. [19] Elias, L.S., Konzen, D., Krebs, J.M., Zavascki, A.P., The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J Antimicrob Chemother 65 (2010), 2231–2237.
20. [20] Zavascki, A.P., Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside. Expert Rev Anti Infect Ther 12 (2014), 531–533.
21. [21] Dubrovskaya, Y., Prasad, N., Lee, Y., Esaian, D., Figueroa, D.A., Tam, V.H., Risk factors for nephrotoxicity onset associated with polymyxin B therapy. J Antimicrob Chemother 70 (2015), 1903–1907.
22. [22] Pogue, J.M., Martin, E.T., Kaye, K.S., Marchaim, D., Hayakawa, K., Discordance in reported rates of nephrotoxicity associated with colistin: a systematic review to analyze the role of dose and definition. In: 25th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); 25–28 April 2015; Copenhagen, Denmark. Basel, Switzerland: ECCMID, 2015 P0720.
23. [23] Landman, D., Georgescu, C., Martin, D.A., Quale, J., Polymyxins revisited. Clin Microbiol Rev 21 (2008), 449–465.
24. [24] Sakura, N., Sakura, N., Itoh, T., Uchida, Y., Ohki, K., Okimura, K., et al. The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull Chem Soc Jpn 77 (2004), 1915–1924.
25. [25] Vaara, M., Sader, H.S., Rhomberg, P.R., Jones, R.N., Vaara, T., Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. J Antimicrob Chemother 68 (2013), 636–639.
26. [26] Okimura, K., Ohki, K., Sato, Y., Ohnishi, K., Sakura, N., Semi-synthesis of polymyxin B (2–10) and colistin (2–10) analogs employing the trichloroethoxycarbonyl (Troc) group for side chain protection of α,γ-diaminobutyric acid residues. Chem Pharm Bull (Tokyo) 55 (2007), 1724–1730.
27. [27] Brink, A.J., Richards, G.A., Colombo, G., Bortolotti, F., Colombo, P., Jehl, F., Multicomponent antibiotic substances produced by fermentation: implications for regulatory authorities, critically ill patients and generics. Int J Antimicrob Agents 43 (2014), 1–6.
28. [28] Kassamali, Z., Prince, R.A., Danziger, L.H., Rotschafer, J.C., Rhomberg, P.R., Jones, R.N., Microbiological assessment of polymyxin B components tested alone and in combination. Antimicrob Agents Chemother 59 (2015), 7823–7825.
29. [29] Karaiskos, I., Friberg, L.E., Pontikis, K., Ioannidis, K., Tsagkari, V., Galani, L., et al. Colistin population pharmacokinetics after application of a loading dose of 9 MU colistin methanesulfonate in critically ill patients. Antimicrob Agents Chemother 59 (2015), 7240–7248.
30. [30] Roberts, K.D., Azad, M.A.K., Wang, J., Horne, A.S., Thompson, P.E., Nation, R.L., et al. Antimicrobial activity and toxicity of the major lipopeptide components of polymyxin B and colistin: last-line antibiotics against multidrug-resistant Gram-negative bacteria. ACS Infect Dis 11 (2015), 568–575.